OnePlan recently attended the Biopharma PPM in Clinical Research & Development Summit, hosted by Why Summits in Philadelphia. The event brought together portfolio, program, and R&D leaders across the life sciences industry to discuss how organizations are managing increasingly complex pipelines while under pressure to accelerate development timelines. With a smaller, curated group of attendees, the conversations were direct and grounded in real operational challenges. Here’s what we’re hearing consistently from leaders working across clinical and R&D portfolios.
Development Timelines Are Under Constant Pressure
Across conversations, one reality was clear. Teams are being asked to move faster across every phase of development while managing more complexity than ever before. Pipelines are expanding. Modalities are diversifying. Regulatory expectations continue to evolve. At the same time, internal teams are expected to maintain precision in planning, forecasting, and execution. Many organizations acknowledged that their current systems were not built for this level of demand. Disconnected tools and manual processes are slowing down decisions at the exact moment speed matters most.
AI Has Moved Into the Execution Layer
AI was not discussed as a future capability. It is already expected to play a role in how programs are planned and managed.
What stood out was the shift in expectations. Leaders are not looking for standalone AI features. They are looking for AI that is embedded directly into portfolio workflows.
The focus areas were consistent:
- Reducing manual effort in planning and reporting
- Identifying risks earlier in the development lifecycle
- Improving the quality and speed of portfolio-level decisions
There is little appetite for experimentation without clear outcomes. Teams want AI that supports real decisions tied to timelines, resources, and pipeline performance.
Portfolio Visibility Remains a Core Gap
Even among mature organizations, visibility across the full portfolio remains limited.
Common challenges included:
- Inconsistent views of resource capacity across functions
- Limited ability to model the downstream impact of changes
- Fragmented data across clinical, financial, and operational systems
Without a unified view, tradeoff decisions become slower and more subjective. This becomes especially critical in clinical development, where small delays or misaligned priorities can have significant downstream impact.
A More Candid Exchange Than Typical Industry Events
The format of the Why Summits event played a role in the quality of the discussion. The smaller setting allowed for direct, candid conversations between peers. Attendees shared real constraints, not just high-level strategies. That level of transparency made it easier to identify where organizations are aligned and where gaps still exist across the industry.
Where OnePlan Supports Life Sciences Teams
The themes from the summit align closely with what we see across life sciences organizations working to modernize their portfolio management approach. Teams need a way to connect long-term strategy with day-to-day execution across clinical and R&D portfolios. They need visibility into how resources, timelines, and investments interact. They also need to evaluate scenarios quickly as programs shift.
OnePlan supports these needs by bringing portfolio planning, resource management, financials, and scenario modeling into a single platform. For life sciences teams, this means:
- Clear visibility across the full development portfolio
- The ability to model and compare scenarios before making decisions
- Integrated financial and resource planning aligned to program timelines
- AI-driven insights that reduce manual effort and support faster decisions
Final Takeaway
The takeaway is clear. Managing clinical and R&D portfolios now requires real-time visibility, integrated planning, and faster decision cycles. OnePlan is built to support this shift, giving life sciences teams the ability to align resources, timelines, and investments while using AI to reduce manual effort and improve decision quality across the portfolio.
